)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Bionano Genomics
Bionano Genomics (BNGO) investor relations material
Bionano Genomics Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary10 Nov, 2026
Executive summary
Q3 revenue was $8.276M, up 12% YoY; flow-cell sales rose 18% to a quarterly record of 9,870, and adjusted gross margin increased to 48%.
Q3 net loss narrowed to $6.453M from $8.503M; 9M revenue rose 13% to $23.134M, while 9M net loss widened to $22.179M.
Financial highlights
Q3 GAAP revenue was $8.276M vs. $7.367M; GAAP gross profit was $3.949M vs. $3.370M.
Operating expenses decreased 12% YoY to $10.5M; adjusted operating expenses were $8.807M vs. $9.658M, down 9%.
Q3 net loss was $6.453M vs. $8.503M; 9M net loss was $22.179M vs. $18.462M.
9M revenue was $23.134M vs. $20.557M; operating loss was $21.651M vs. $24.803M.
Outlook and guidance
FY 2026 revenue guidance was reiterated at $31M–$33M, representing 9%–16% growth over 2025; results were expected near the midpoint.
Current plans indicate funding for operating expenses and capital needs into at least Q1 2027, but additional capital is needed to support operations beyond the next 12 months.
Production constraints are expected to ease toward year-end; capacity is planned to double by mid-2027 and cover projected 2027 demand and most of 2028.
Ionic System for OGM is planned for limited market release in Q4 2026.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Bionano Genomics
- $400M shelf financing flexibility meets substantial going-concern and capital needs.BNGO
Registration filing - Warrant exercise could add 1.33M shares and up to ~$90M gross proceeds.BNGORegistration filing
- OGM adoption accelerates with regulatory approvals, reimbursement gains, and robust revenue growth.BNGOH.C. Wainwright 28th Annual Global Investment Conference
- Q2 2026 revenue rose 21% to $8.2M, with margin gains but ongoing liquidity concerns.BNGOQ2 2026
- Strategic shift to recurring revenue and cost efficiency aims for profitability and sustained growth.BNGOH.C. Wainwright 26th Annual Global Investment Conference 2024
- Q1 2026 revenue up 4% to $6.7M, gross margin at 49%, but net loss deepened and capital needs remain.BNGOQ1 2026
- Seeks to raise $400 million for operations and R&D amid ongoing losses and capital needs.BNGORegistration filing
- Annual meeting to vote on director elections, executive pay, and auditor ratification.BNGOProxy filing
- Board recommends approval of director elections, executive pay, and auditor ratification, with ESG focus.BNGOProxy filing
Next Bionano Genomics earnings date
Q4 202625 Mar, 2027
Bionano Genomics
Next Bionano Genomics earnings date
Q4 202625 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Bionano Genomics provides genome analysis software solutions for structural variation discovery and genome assembly enhancement. The Company's Saphyr system is a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the characterization of these targets. The company was founded in 2003 and is headquartered in San Diego, California.